Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Risperidone 2mg tablets get higher concessionary price after review

The October concessionary price for risperidone 2mg tablets has been “redetermined” from £1.80 to £20.00, the Pharmaceutical Services Negotiating Committee (PSNC) has announced.

The price concession is now set at £20.00 for a pack of 60 tablets and will be automatically applied to any prescriptions submitted in the October prescription bundle, PSNC said.

The increase comes “following further representation from PSNC”, the negotiator said.

“Originally imposed at a price of £1.80 by the Department of Health and Social Care, PSNC requested a review of the concessionary price on behalf of community pharmacy contractors,” PSNC added.

A total of 44 concessionary prices were announced for October. An initial nine prices were announced on October 23, followed by 15 on October 26 and a further 20 on November 1.

Does this new price reflect what you paid in October?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel